3-(8-methoxy-1-methyl-2-oxo-7-phenyl-3H-1,4-benzodiazepin-5-yl)benzamide | 855170-53-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 3-(8-methoxy-1-methyl-2-oxo-7-phenyl-3H-1,4-benzodiazepin-5-yl)benzamide
• 英文别名: 3-(8-methoxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e]-[1,4]diazepin-5-yl)benzamide；ND-7001；3-(2,3-Dihydro-8-methoxy-1-methyl-2-oxo-7-phenyl-1H-1,4-benzodiazepin-5-yl)benzamide
• CAS: 855170-53-5
• 化学式: C₂₄H₂₁N₃O₃
• 分子量: 399.449
• InChiKey: WYTGWTBNDXWMMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  85
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-(8-methoxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzonitrile 在 sodium hydroxide 、 乙醇 、 水 、 双氧水 作用下， 反应 16.0h， 以72%的产率得到3-(8-methoxy-1-methyl-2-oxo-7-phenyl-3H-1,4-benzodiazepin-5-yl)benzamide
  参考文献：
  名称：

  Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof

  摘要：

  该发明涉及具有PDE2抑制活性的化合物，以及通过给予该化合物进行治疗的方法，特别是用于治疗中枢或外周神经系统的各种疾病。还涉及包含该化合物的药物组合物以及制备该化合物的方法。通式(I)的化合物：

  公开号：

  EP1548011A1

文献信息

• Benzo-1,4-diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof
  申请人：Abarghaz Mustapha

  公开号：US20070123519A1

  公开（公告）日：2007-05-31

  The invention relates to compounds having PDE2 inhibitory activities, as well as therapeutic methods by administering said compounds, in particular for treating various diseases of the central or peripheral nervous system. It further deals with pharmaceutical compositions comprising said compounds and methods for preparing said compounds.

  该发明涉及具有PDE2抑制活性的化合物，以及通过给予该化合物的治疗方法，特别是用于治疗中枢或外周神经系统的各种疾病。它还涉及包含该化合物的药物组合物和制备该化合物的方法。
• Treatment of tachycardia
  申请人：OSLO UNIVERSITY HOSPITAL HF

  公开号：US11419874B2

  公开（公告）日：2022-08-23

  The invention provides compounds which are selective PDE2 inhibitors for use in the treatment of tachycardia or tachyarrhythmia Such compounds are particularly suitable for use in the treatment of any of the following conditions: atrial tachycardia, atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia, premature ventricular contractions (PVCs), ventricular fibrillation and ventricular tachycardia, and may be used alone or in combination therapy with other conventional cardiovascular drugs, e.g. beta-blockers. In particular, the invention provides compounds which are selective PDE2 inhibitors for use in the treatment of ventricular tachycardia in patients who are suffering from, or who are at risk of suffering from heart failure, CPVT or long QT syndrome.

  本发明提供了用于治疗心动过速或心动过速性心律失常的选择性 PDE2 抑制剂化合物：心房性心动过速、心房颤动、心房扑动、阵发性室上性心动过速、室性早搏 （PVC）、心室颤动和室性心动过速，可单独使用或与其它常规心血管药物（如 β-受体阻滞剂）联合使用。如β-受体阻滞剂。特别是，本发明提供的化合物是选择性 PDE2 抑制剂，可用于治疗心力衰竭、CPVT 或长 QT 综合征患者的室性心动过速或有此风险的患者的室性心动过速。
• BENZO'1,4 ! DIAZEPIN-2-ONE DERIVATIVES AS PHOSPHODIESTERASE PDE2 INHIBITORS, PREPARATION AND THERAPEUTIC USE THEREOF
  申请人：NEURO3D

  公开号：EP1697332A1

  公开（公告）日：2006-09-06
• PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES
  申请人：Fundación para la Investigación Médica Aplicada

  公开号：EP3185903A1

  公开（公告）日：2017-07-05
• TREATMENT OF TACHYCARDIA
  申请人：OSLO UNIVERSITY HOSPITAL HF

  公开号：US20200345744A1

  公开（公告）日：2020-11-05

  The invention provides compounds which are selective PDE2 inhibitors for use in the treatment of tachycardia or tachyarrhythmia Such compounds are particularly suitable for use in the treatment of any of the following conditions: atrial tachycardia, atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia, premature ventricular contractions (PVCs), ventricular fibrillation and ventricular tachycardia, and may be used alone or in combination therapy with other conventional cardiovascular drugs, e.g. beta-blockers. In particular, the invention provides compounds which are selective PDE2 inhibitors for use in the treatment of ventricular tachycardia in patients who are suffering from, or who are at risk of suffering from heart failure, CPVT or long QT syndrome.